Gland Pharma Q1FY27 Revenue Up 20% to ₹18,003 Cr, PAT Jumps 47%
Gland Pharma reported Q1 FY27 results with revenue at ₹18,003 crore, up 20% YoY. PAT surged 47% to ₹3,170 crore. Both CDMO and B2B segments grew robustly. The company launched 4 new molecules in the USA and anticipates significant revenue from a new CDMO partnership starting in 2029.
The significant increase in revenue and profit, coupled with strategic business growth and new product launches, is expected to have a considerable positive impact on the company's financial performance and market position.
The company reported strong year-on-year growth in revenue and profit, along with positive commentary from the Executive Chairman regarding strategy execution and future growth prospects.
Gland Pharma Limited announced its financial results for the first quarter ended June 30, 2026, reporting record revenues and significant profit growth.
Revenue from operations increased by 20% year-on-year to ₹18,003 crore, up from ₹15,056 crore in Q1 FY26. Profit After Tax (PAT) saw a substantial jump of 47% year-on-year, reaching ₹3,170 crore, compared to ₹2,155 crore in the same period last year. The PAT margin improved to 18% from 14% in Q1 FY26.
Adjusted EBITDA also grew by 37% year-on-year to ₹5,102 crore, with an adjusted EBITDA margin of 28%, up from 25% in the prior year quarter. Gross profit increased by 19% to ₹11,759 crore.
Both the Contract Development & Manufacturing Operations (CDMO) and Business-to-Business (B2B) segments contributed equally, accounting for 50% of revenues each. The CDMO business grew by 20% year-on-year, while the B2B business saw a 19% increase.
Geographically, the USA market showed strong performance with a 32% year-on-year revenue growth, contributing ₹9,810 crore. Europe also reported a 20% increase in revenue to ₹3,954 crore.
In business highlights, Gland Pharma launched 4 molecules in the USA, including Multi-Vitamin and Leucovorin calcium. The company filed three ANDAs and received approvals for seven in Q1 FY27. A significant CDMO partnership with a global pharmaceutical company is expected to generate an annualized revenue of USD 90-100 million, with revenues commencing from calendar year 2029.
The company has scheduled an earnings call for August 10th, 2026, at 6:30 PM IST to discuss these results.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.